The therapeutic effect of PCSK9 inhibitors on dyslipidemia: one-year follow up

• Autori principali: Maryam Moshkani Farahani (Autore), Alireza Nasiri (Autore), Mahdi Salari (Autore), Ali Shamsedini (Autore)
• Natura: Libro
• Pubblicazione: PAGEPress Publications, 2024-09-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Despite the availability of statins and lifestyle modifications, many patients with Dyslipidemia struggle to achieve optimal low-density lipoprotein cholesterol (LDL-C) control. PCSK9 inhibitors offer a promising new therapeutic option with superior LDL-C lowering efficacy compared to statins. Howev...